Abstract
Severe traumatic brain injury (TBI), with its diverse heterogeneity and prolonged secondary pathogenesis, remains a clinical challenge. Current medical management of TBI patients appropriately focuses on specialized prehospital care, intensive acute clinical care, and long-term rehabilitation but lacks clinically proven effective management with neuroprotective and neuroregenerative agents. Clinical studies thus far have failed to identify an effective treatment strategy as they typically have targeted single enzymatic factors in an attempt to identify a pharmacologic target rather than considering multiple mechanisms of injury with a more holistic approach. A combination of targets controlling aspects of neuroprotection, neuroinflammation, and regeneration is needed. Omega-3 fatty acids (ω-3FA) offer the advantage of this poly-target approach. Although further clinical trial research is needed to establish the true advantage of using ω-3FA, there is a growing body of strong preclinical evidence, and clinical experience suggests that benefits may be possible from aggressively adding substantial amounts of ω-3FA to optimize the nutritional foundation of severe TBI patients. Administration of substantial and optimal doses of ω-3FA early in the course of TBI, even in the prehospital or emergency department setting, has the potential to improve outcomes from this potentially devastating public health problem. With evidence of unsurpassed safety and tolerability, ω-3FA should be considered mainstream, conventional medicine, if conventional medicine can overcome its inherent bias against nutritional, non-pharmacologic therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ω-3FAs:
-
Omega-3 polyunsaturated fatty acids
- ω-6FAs:
-
Omega-6 polyunsaturated fatty acids
- AA:
-
Arachidonic acid
- ALA:
-
Alpha-linolenic acid
- APP:
-
β-Amyloid precursor protein
- BDNF:
-
Brain-derived neurotrophic factor
- CaMKII:
-
Calcium/calmodulin-dependent kinase II
- COX:
-
Cyclooxygenase
- CREB:
-
cAMP-responsive element binding
- CT:
-
Computerized tomography
- DAI:
-
Diffuse axonal injury
- DHA:
-
Docosahexaenoic acid
- DHA-Alb:
-
DHA complexed to albumin
- EPA:
-
Eicosapentaenoic acid
- FDA:
-
Food and Drug Administration (United States)
- GCS:
-
Glasgow Coma Scale
- GRAS:
-
Generally recognizable as safe
- H/I:
-
Hypoxic–ischemic
- ICP:
-
Intracranial pressure
- ICU:
-
Intensive care unit
- IL-6:
-
Interleukin-6
- IL-1β:
-
Interleukin-1 beta
- IND:
-
Investigational new drug
- LOX:
-
Lipoxygenase
- LTB4:
-
Leukotriene B4
- Mg:
-
Milligrams
- MRI:
-
Magnetic resonance imaging
- NPD1:
-
Neuroprotectin D1
- PE:
-
Phosphatidylethanolamine
- PEG:
-
Percutaneous endoscopic gastrostomy
- PGE2:
-
Prostaglandin E2
- PLA2:
-
Phospholipase A2
- PS:
-
Phosphatidylserine
- RXR:
-
Retinoid X receptors
- SCI:
-
Spinal cord injury
- SIR-2:
-
Silent information regulator 2
- SOD:
-
Superoxide dismutase
- Syn-1:
-
Synapsin I
- TBI:
-
Traumatic brain injury
- TNF-α:
-
Tumor necrosis factor alpha
References
Armonda R, Bell R, Vo A, et al. Wartime traumatic cerebral vasospasm: recent review of combat casualties. Neurosurgery. 2006;59:1215–25.
Armstead W. Brain injury impairs prostaglandin cerebrovasodilation. J Neurotrauma. 1998;15:721–9.
Armstead W. Superoxide generation links protein kinase C activation to impaired ATP-sensitive K+ channel function after brain injury. Stroke. 1999;30:153–9.
Bailes J, Mills J. Docosahexaenoic acid reduces traumatic axonal injury in a rodent head injury model. J Neurotrauma. 2010;27:1617–24.
Bazan N, Molina M, Gordon W. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Ann Rev Nutr. 2011;31:321–51.
Belayev L, Marcheselli V, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke. 2005;36:118–23.
Berman D, Mozurkewich E, Liu Y, Barks J. Docosahexaenoic acid pretreatment confers neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia. Am J Ob Gyn. 2009;200(305):e1–6.
Berman D, Liu Y, Barks J, Mozurkewich E. Treatment with docosahexaenoic acid after hypoxia-ischemia improves forepaw placing in a rat model of perinatal hypoxia-ischemia. Am J Ob Gyn. 2010;203(385):e1–5.
Berman D, Mozurkewich E, Liu Y, et al. Docosahexaenoic acid augments hypothermic neuroprotection in a neonatal rat asphyxia model. Neonatology. 2013;104:71–8.
Blasbalg T, Hibbeln J, Ramsden C, et al. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011;93:950–62.
Bradbury J. Docosahexaenoic Acid (DHA): an ancient nutrient for the modern human brain. Nutrients. 2011;3:529–54.
Calder P. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2:355–74.
Chang M, Puder M, Gura K. The use of fish oil lipid emulsion in the treatment of Intestinal Failure Associated Liver Disease (IFALD). Nutrients. 2012;4:1828–50.
Chang C, Kuan Y, Li J, et al. Docosahexaenoic acid reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. J Nutr Biochem. 2013;24:2127–37.
Coronado V, McGuire L, Sarmiento K, et al. Trends in Traumatic Brain Injury in the U.S. and the public health response: 1995–2009. J Safety Res. 2012;43:299–307.
Danaei G, Ding E, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;28:e1000058.
Diaz-Arrastia R, Kochanek P, Bergold P, et al. Pharmacotherapy of traumatic brain injury: state of the science and the road forward report of the department of defense neurotrauma pharmacology workgroup. J Neurotrauma. 2014;31(2):135–58.
Eady T, Khoutorova L, Atkins K, et al. Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window. Exp Transl Stroke Med. 2012;4:19.
Eady T, Khoutorova L, Anzola D, et al. Acute treatment with docosahexaenoic acid complexed to albumin reduces injury after a permanent focal cerebral ischemia in rats. PLoSOne. 2013;8:e77237.
Eady T, Khoutorova L, Obenaus A, et al. Docosahexaenoic acid complexed to albumin provides neuroprotection after experimental stroke in aged rats. Neurobiol Dis. 2014;62:1–7.
EFSA. Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012;10:2815. http://www.efsa.europa.eu/en/efsajournal/pub/2815.htm Accessed 15 December 2013.
Farooqui A. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Curr Med Chem. 2012;19:532–43.
Farooqui A, Hiser B, Barnes S, Litofsky N. Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury. J Neurosurg. 2013;119:1576–82.
Faul M, Xu L, Wald M, Coronado V. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths 2002–2006. In: Centers for Disease Control and Prevention; 2010. http://www.cdc.gov/traumaticbraininjury/pdf/blue_book.pdf. Accessed 15 Dec 2013.
Figueroa J, Cordero K, Llán M, De Leon M. Dietary omega-3 polyunsaturated fatty acids improve the neurolipidome and restore the DHA status while promoting functional recovery after experimental spinal cord injury. J Neurotrauma. 2013;16:1–16.
Goldstein J. No stone unturned: a father’s memoir of his son’s encounter with traumatic brain injury. Dulles: Potomac Books; 2012. p. 242.
Gomez-Pinilla F. The influences of diet and exercise on mental health through hormesis. Ageing Res Rev. 2008;7:49–62.
Härtl R, Gerber L, Ni Q, Ghajar J. Effect of early nutrition on deaths due to severe traumatic brain injury. J Neurosurg. 2008;109:50–6.
Hasadsri L, Wang B, Lee J, et al. Omega-3 fatty acids as a putative treatment for traumatic brain injury. J Neurotrauma. 2013;30:897–906.
Hayden M, Jandial R, Duenas H, et al. Pediatric concussions in sports: a simple and rapid assessment tool for concussive injury in children and adults. Childs Nerv Syst. 2007;23:431–5.
Heller A, Rössler S, Litz R, et al. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med. 2006;34:972–9.
Hemphill M, Dabiri B, Gabriele S, et al. A possible role for integrin signaling in diffuse axonal injury. PLoSOne. 2011;6:e2289.
Katz R. Investigational new drug submission. In: Food and Drug Administration; 2011. http://www.ibrfinc.org/media/fda.pdf. Accessed 15 Dec 2013.
Kim H. Biochemical and biological functions of docosahexaenoic acid in the nervous system: modulation by ethanol. Chem Phys Lipids. 2008;153:34–46.
Kim H, Spector A. Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukot Essent Fat Acids. 2013;88:121–5.
Kochanek P, Clark R, Jenkins L. TBI: pathology. In: Zasler N, Katz D, Zafonte R, editors. Brain injury medicine: principles and practice. New York: Demos Medical Publishing; 2007. p. 81–92.
Kohli P, Levy B. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol. 2009;158:960–71.
Lee B, Newberg A. Neuroimaging in traumatic brain imaging. J Am Soc Exp Neurother. 2005;2:372–83.
Lewis M, Bailes J. Neuroprotection for the warrior: dietary supplementation with omega-3 fatty acids. Mil Med. 2011;176:1120–7.
Lewis M, Hibbeln J, Johnson J, et al. Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. J Clin Psych. 2011;72:1585–90.
Lewis M, Ghassemi P, Hibbeln J. Therapeutic use of omega-3 fatty acids in severe head trauma. Am J Emerg Med. 2013;31:5–8.
Ling G, Marshall S. Management of traumatic brain injury in the intensive care unit. Neurol Clin. 2008;26:vii.
Ling G, Bandak F, Armonda R, et al. Explosive blast neurotrauma. J Neurotrauma. 2009;26:815–25.
Maas A, Roozenbeek B, Manley G. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics. 2010;7:115–26.
Mayer K, Seeger W. Fish oil in critical illness. Curr Op Clin Nutr Metabolic Care. 2008;11:121–7.
McClave S, Martindale R, Vanek V, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). J Parenteral Enteral Nutr. 2009;33:277–316.
Meythaler J, Peduzzi J, Eleftheriou E, Novack T. Current concepts: diffuse axonal injury-associated traumatic brain injury. Arch Phys Med Rehab. 2001;82:1461–71.
Michael-Titus A. Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fat Acids. 2007;77:295–300.
Michael-Titus A, Priestley J. Omega-3 fatty acids and traumatic neurological injury: from neuroprotection to neuroplasticity? Trends Neurosci. 2014;37:30–8.
Mills J, Bailes J, Sedney C, et al. Omega-3 fatty acid supplementation and reduction of traumatic axonal injury in a rodent head injury model. J Neurosurg. 2011a;114:77–84.
Mills J, Hadley K, Bailes J. Dietary supplementation with the omega-3 fatty acid docosahexaenoic acid in traumatic brain injury. J Neurosurg. 2011b;68:474–81.
Moore S, Yoder E, Murphy S, Dutton G, Spector A. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J Neurochem. 1991;56:518–24.
Pan H, Kao T, Ou Y, et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem. 2009;20:715–25.
Park E, Bell J, Baker A. Traumatic brain injury: can the consequences be stopped? Can Med Assoc. 2008;178:1163–70.
Pradelli L, Eandi M, Povero M et al. Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation mode. Clin Nutr. 2014;33(5):785–92.
Ramesh G, MacLean A, Philipp M. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediat Inflamm. 2013:480739. Epub 2013 Aug 12.
Rashid M, Katakura M, Kharebava G, et al. N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. J Neurochem. 2013;125:869–84.
Reilly P. The impact of neurotrauma on society: an international perspective. In: Weber J, Maas A, editors. Neurotrauma: new insights into pathology and treatment. Amsterdam: Elsevier; 2007. p. 5–7.
Roberts L, Bailes J, Dedhia H, et al. Surviving a mine explosion. J Am Coll Surg. 2008;207:276–83.
Rodríguez-Rodríguez A, Egea-Guerrero J, Murillo-Cabezas F, Carrillo-Vico A. Oxidative stress in traumatic brain injury. Curr Med Chem. 2014;21(10):1201–11.
Rosenberg G. Ischemic brain edema. Prog Cardiovasc Dis. 1999;42:209–16.
Russell K, Berman N, Gregg P, Levant B. Fish oil improves motor function, limits blood-brain barrier disruption, and reduces Mmp9 gene expression in a rat model of juvenile traumatic brain injury. Prostaglandins Leukot Essent Fat Acids. 2014;90:5–11.
Saatman K, Duhaime A, Bullock R, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25:719–38.
Salem N, Litman B, Kim H, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001;36:945–59.
Selassie A, Zaloshnja E, Langlois J, et al. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J Head Trauma Rehabil. 2008;23:123–31.
Shin S, Dixon C. Oral fish oil restores striatal dopamine release after traumatic brain injury. Neurosci Lett. 2011;496:168–71.
Smith D, Meaney D. Axonal damage in traumatic brain injury. Neuroscientist. 2000;6:483–95.
Stein D, Wright D, Kellermann A. Does progesterone have neuroprotective properties? Ann Emerg Med. 2008;51:164–72.
Streit W, Mrak R, Griffin W. Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm. 2004;1:14.
Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725–30.
Wang T, Van K, Gavitt B, et al. Effect of fish oil supplementation in a rat model of multiple mild traumatic brain injuries. Restor Neurol Neurosci. 2013a;31:647–59.
Wang X, Dong Y, Han X, et al. Nutritional support for patients sustaining traumatic brain injury: a systematic review and meta-analysis of prospective studies. PLoSOne. 2013b;8:e58838.
Wasserman J, Feldman J, Koenigsberg R. Diffuse axonal injury imaging. Medscape. 2012. http://emedicine.medscape.com/article/339912. Accessed 22 Dec 2013.
Weimann A, Braga M, Harsanyi L, et al. ESPEN guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr. 2006;25:224–44.
Williams J, Mayurasakorn K, Vannucci S, et al. N-3 fatty acid rich triglyceride emulsions are neuroprotective after cerebral hypoxic-ischemic injury in neonatal mice. PloSOne. 2013;8:e56233.
Wu A, Ying Z, Gomez-Pinilla F. Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma. 2007;24:1587–95.
Wu A, Ying Z, Gomez-Pinilla F. The salutary effects of DHA dietary supplementation on cognition, neuroplasticity, and membrane homeostasis after brain trauma. J Neurotrauma. 2011;28:2113–22.
Wu A, Ying Z, Gomez-Pinilla F. Exercise facilitates the action of dietary DHA on functional recovery after brain trauma. Neuroscience. 2013;248:655–63.
Xiong Y, Mahmood A, Chopp M. Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009;14:67–84.
Yealy D, Hogan D. Imaging after head trauma. Who needs what? Emerg Med Clin North Am. 1991;9:707–17.
Zaloshnja E, Miller T, Langlois J, Selassie A. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States. J Head Trauma Rehabil. 2005;23:394–400.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this entry
Cite this entry
Lewis, M.D. (2015). Severe Head Trauma and Omega-3 Fatty Acids. In: Rajendram, R., Preedy, V.R., Patel, V.B. (eds) Diet and Nutrition in Critical Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7836-2_114
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7836-2_114
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7837-9
Online ISBN: 978-1-4614-7836-2
eBook Packages: MedicineReference Module Medicine